Cambrex expands process R&D capabilities across North America

30 Jan 2018

The expansion at Charles City is in parallel to the investments announced in 2017 at Cambrex’s facility in High Point, North Carolina.

Cambrex has announced an investment to expand chemical and analytical development capabilities at its Charles City, Iowa plant. The project forms part of the company’s strategic plan to increase its development capacity and resources in North America.

Cambrex expands process R&D capabilities across North America

The expansion will see the construction of an additional 2,000 sq.ft. of laboratory space for development projects, and will support the hiring of an additional 14 chemists. The building, installation and validation of equipment is expected to be completed by Q1 2018.

The expansion at Charles City is in parallel to the investments announced in 2017 at Cambrex’s facility in High Point, North Carolina, where a new 11,000 sq.ft. analytical laboratory and 400 sq.ft. pilot plant with a total reactor capacity of 4,000 L are currently being completed. These expansions at High Point will create up to 18 new jobs.

“The Charles City site has seen multiple investments and expansions in manufacturing capacity over the past 5 years to meet market demand, and this, in turn, has led to us needing to increase the capacity of the supporting development and analytical functions,” commented Joe Nettleton, Vice President US Operations, Cambrex. “Our strategy in expanding the development capabilities across the sites at both Charles City and High Point is to ensure both facilities are harmonized and can function synergistically so that projects can be seamlessly transferred between the two.”

Cambrex’s Charles City, Iowa facility is located on a 45-acre site and manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances. The High Point site, formerly PharmaCore, Inc., was acquired by Cambrex in October 2016, and produces complex APIs and intermediates in batch sizes from milligrams to 100kg to support clinical trials from Phase I to Phase III.

Read More

Related tags

Market News

Related news

Allergan to establish R&D presence in Cambridge, Massachusetts

Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Read more 
Expedeon signs supply and license agreement for is Lightning-Link technology

Expedeon signs supply and license agreement for is Lightning-Link technology

9 Jan 2019

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Read more 
Lilly to bag Loxo Oncology for $8 billion

Lilly to bag Loxo Oncology for $8 billion

8 Jan 2019

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Read more 
Catalent to double its commercial biomanufacturing capacity

Catalent to double its commercial biomanufacturing capacity

7 Jan 2019

The $200-million expansion will support customers’ development programs and commercial launches.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
Cambrex completes acquisition of Avista Pharma Solutions

Cambrex completes acquisition of Avista Pharma Solutions

2 Jan 2019

Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.

Read more 
Novartis offers to acquire CellforCure

Novartis offers to acquire CellforCure

1 Jan 2019

Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

Read more 
BMS receives offer from Taisho to purchase UPSA

BMS receives offer from Taisho to purchase UPSA

30 Dec 2018

The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

Read more 
Recipharm to potentially end operations in Ashton-under-Lyne facility

Recipharm to potentially end operations in Ashton-under-Lyne facility

24 Dec 2018

The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more